SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0028 4793 OR L773:1533 4406 "

Sökning: L773:0028 4793 OR L773:1533 4406

  • Resultat 581-590 av 708
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
581.
  •  
582.
  • Ranstam, Jonas, et al. (författare)
  • Oral-Contraceptive Use and the Risk of Breast Cancer
  • 1987
  • Ingår i: New England Journal of Medicine. - 0028-4793. ; 316:3, s. 162-164
  • Tidskriftsartikel (refereegranskat)abstract
    • To the Editor: The study on oral-contraceptive use and the risk of breast cancer from the Centers for Disease Control (CDC) and the National Institute of Child Health and Human Development (Aug. 14 issue)1 seems to be reassuring for oral-contraceptive users. But, as stated in the editorial by Shapiro in the same issue,2 there are some weak points that need further elucidation. We have found a highly increased risk of breast cancer among young (teenage) oral-contraceptive users in southern Sweden.3 From incidence figures for Sweden, an increase in premenopausal breast cancer can be seen to have started in about 1975,…
  •  
583.
  • Rawshani, Aidin, 1991, et al. (författare)
  • Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.
  • 2017
  • Ingår i: The New England journal of medicine. - 1533-4406. ; 376:15, s. 1407-1418
  • Tidskriftsartikel (refereegranskat)abstract
    • Long-term trends in excess risk of death and cardiovascular outcomes have not been extensively studied in persons with type 1 diabetes or type 2 diabetes.We included patients registered in the Swedish National Diabetes Register from 1998 through 2012 and followed them through 2014. Trends in deaths and cardiovascular events were estimated with Cox regression and standardized incidence rates. For each patient, controls who were matched for age, sex, and county were randomly selected from the general population.Among patients with type 1 diabetes, absolute changes during the study period in the incidence rates of sentinel outcomes per 10,000 person-years were as follows: death from any cause, -31.4 (95% confidence interval [CI], -56.1 to -6.7); death from cardiovascular disease, -26.0 (95% CI, -42.6 to -9.4); death from coronary heart disease, -21.7 (95% CI, -37.1 to -6.4); and hospitalization for cardiovascular disease, -45.7 (95% CI, -71.4 to -20.1). Absolute changes per 10,000 person-years among patients with type 2 diabetes were as follows: death from any cause, -69.6 (95% CI, -95.9 to -43.2); death from cardiovascular disease, -110.0 (95% CI, -128.9 to -91.1); death from coronary heart disease, -91.9 (95% CI, -108.9 to -75.0); and hospitalization for cardiovascular disease, -203.6 (95% CI, -230.9 to -176.3). Patients with type 1 diabetes had roughly 40% greater reduction in cardiovascular outcomes than controls, and patients with type 2 diabetes had roughly 20% greater reduction than controls. Reductions in fatal outcomes were similar in patients with type 1 diabetes and controls, whereas patients with type 2 diabetes had smaller reductions in fatal outcomes than controls.In Sweden from 1998 through 2014, mortality and the incidence of cardiovascular outcomes declined substantially among persons with diabetes, although fatal outcomes declined less among those with type 2 diabetes than among controls. (Funded by the Swedish Association of Local Authorities and Regions and others.).
  •  
584.
  •  
585.
  • Redfors, Björn, et al. (författare)
  • Takotsubo (Stress) Cardiomyopathy.
  • 2015
  • Ingår i: The New England journal of medicine. - 1533-4406. ; 373:27, s. 2688-9
  • Tidskriftsartikel (refereegranskat)
  •  
586.
  • Reid, IR, et al. (författare)
  • Intravenous zoledronic acid in postmenopausal women with low bone mineral density
  • 2002
  • Ingår i: New England Journal of Medicine. - 0028-4793. ; 346:9, s. 653-661
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Bisphosphonates are effective agents for the management of osteoporosis. Their low bioavailability and low potency necessitate frequent administration on an empty stomach, which may reduce compliance. Gastrointestinal intolerance limits maximal dosing. Although intermittent intravenous treatments have been used, the optimal doses and dosing interval have not been systematically explored. Methods: We studied the effects of five regimens of zoledronic acid, the most potent bisphosphonate, on bone turnover and density in 351 postmenopausal women with low bone mineral density in a one-year, randomized, double-blind, placebo-controlled trial. Women received placebo or intravenous zoledronic acid in doses of 0.25 mg, 0.5 mg, or 1 mg at three-month intervals. In addition, one group received a total annual dose of 4 mg as a single dose, and another received two doses of 2 mg each, six months apart. Lumbar-spine bone mineral density was the primary end point. Results: There were similar increases in bone mineral density in all the zoledronic acid groups to values for the spine that were 4.3 to 5.1 percent higher than those in the placebo group (P<0.001) and values for the femoral neck that were 3.1 to 3.5 percent higher than those in the placebo group (P<0.001). Biochemical markers of bone resorption were significantly suppressed throughout the study in all zoledronic acid groups. Myalgia and pyrexia occurred more commonly in the zoledronic acid groups, but treatment-related dropout rates were similar to that in the placebo group. Conclusions: Zoledronic acid infusions given at intervals of up to one year produce effects on bone turnover and bone density as great as those achieved with daily oral dosing with bisphosphonates with proven efficacy against fractures, suggesting that an annual infusion of zoledronic acid might be an effective treatment for postmenopausal osteoporosis.
  •  
587.
  •  
588.
  •  
589.
  • Ridker, P. M., et al. (författare)
  • Antiinflammatory therapy with canakinumab for atherosclerotic disease
  • 2017
  • Ingår i: New England Journal of Medicine. - 0028-4793. ; 377:12, s. 1119-1131
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. METHODS: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P=0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P=0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P=0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P=0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P=0.31). CONCLUSIONS: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. Copyright © 2017 Massachusetts Medical Society.
  •  
590.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 581-590 av 708
Typ av publikation
tidskriftsartikel (698)
forskningsöversikt (5)
annan publikation (3)
konferensbidrag (1)
recension (1)
Typ av innehåll
refereegranskat (542)
övrigt vetenskapligt/konstnärligt (164)
populärvet., debatt m.m. (2)
Författare/redaktör
Adami, HO (12)
Schulman, S (12)
Diaz, R. (11)
Swedberg, Karl, 1944 (11)
Rosengren, Annika, 1 ... (11)
Wallentin, Lars (10)
visa fler...
Harrington, Robert A (9)
Fröbert, Ole, 1964- (8)
Collins, R (8)
Melander, Olle (8)
Wallentin, Lars, 194 ... (8)
Yusuf, S. (7)
Holmberg, Lars (7)
Held, Claes, 1956- (7)
Leiter, Lawrence A (7)
Bill-Axelson, Anna (7)
Olsson, Håkan (6)
Bergh, J (6)
Solomon, S. D. (6)
Nyren, O (6)
Adami, Hans Olov (6)
Cnattingius, S (6)
Wedel, Hans (6)
Granger, Christopher ... (6)
Vinereanu, Dragos (6)
Pais, P. (5)
Svensson, Leif (5)
Nilsson, Peter (5)
Groop, Leif (5)
Moreau, P (5)
Ponikowski, Piotr (5)
Aspenberg, Per (5)
Toni, D. (5)
Häggman, Michael (5)
Koenig, W. (5)
Trichopoulos, D (5)
Bergstrom, R (5)
McMurray, John J. V. (5)
Erlinge, David (5)
Garmo, Hans (5)
Hugosson, Jonas, 195 ... (5)
Bjartell, Anders (5)
Lewis, BS (5)
Franks, Paul W. (5)
James, Stefan, 1964- (5)
Sjöström, Lars (5)
Orho-Melander, Marju (5)
Armstrong, Paul W. (5)
Lopes, Renato D. (5)
Witt, N (5)
visa färre...
Lärosäte
Karolinska Institutet (380)
Uppsala universitet (150)
Lunds universitet (131)
Göteborgs universitet (110)
Linköpings universitet (54)
Umeå universitet (48)
visa fler...
Örebro universitet (32)
Högskolan i Borås (5)
Kungliga Tekniska Högskolan (4)
Högskolan Dalarna (4)
Chalmers tekniska högskola (3)
Linnéuniversitetet (3)
Södertörns högskola (2)
Marie Cederschiöld högskola (2)
Stockholms universitet (1)
Mälardalens universitet (1)
Jönköping University (1)
Handelshögskolan i Stockholm (1)
Högskolan i Skövde (1)
Gymnastik- och idrottshögskolan (1)
visa färre...
Språk
Engelska (708)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (330)
Naturvetenskap (8)
Teknik (3)
Samhällsvetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy